

Listing of Claims

1-20. (Canceled)

21. (Currently Amended) A method of ~~ablating, killing, or~~ eliminating ~~normal, benign hyperplastic, and~~ cancerous prostate epithelial cells comprising: providing an antibody bound to a cytotoxic agent which antibody binds to an outer membrane domain of prostate specific membrane antigen having the sequence set forth in SEQ ID NO:128 and contacting said cells with the antibody bound to the cytotoxic agent under conditions effective to permit both binding of the antibody to the outer membrane domain of the prostate specific membrane antigen and ~~ablating, killing, or~~ eliminating said cells.
22. (Canceled).
23. (Currently Amended) A method according to claim 21, wherein said contacting is carried out in a living mammal and comprises: administering the antibody bound to the cytotoxic agent to the mammal under conditions effective to permit both binding of the ~~biological agent~~ antibody bound to the cytotoxic agent to the outer membrane domain of the prostate specific membrane antigen and eliminating ~~killing~~ of said cells.
24. (Previously presented) A method according to claim 23, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously or intramuscularly.

25. (Currently Amended) A method according to claim 21, wherein the antibody bound to the cytotoxic agent is ~~selected from the group consisting of~~ a monoclonal antibody ~~and~~ or a polyclonal antibody.
26. (Canceled).
27. (Currently Amended) A method according to claim 21, wherein the cytotoxic agent bound to the antibody is ~~bound to a substance~~ effective to ~~kill, ablate or~~ eliminate said cells upon binding of the antibody to the outer membrane domain of the prostate specific membrane antigen of said cells.
28. (Canceled).
29. (Currently Amended) A method according to claim 21 ~~28~~, wherein the cytotoxic agent is ~~selected from the group consisting of~~ a drug, a toxin, a radioactive substance, a chemotherapeutic, an enzyme or a molecule ~~and molecules~~ of fungal, viral ~~and~~ or bacterial origin.
30. (Currently Amended) A method according to claim 21, wherein the antibody bound to the cytotoxic agent is in a composition further comprising a physiologically acceptable carrier, diluent, or stabilizer.
31. (Currently Amended) A method according to claim 21, wherein the antibody bound to the cytotoxic agent is in a composition further comprising a pharmaceutically acceptable carrier, diluent, or stabilizer.

Applicants: Ron S. Israeli, et al.
Serial No.: 10/751,346
Filed: January 2, 2004
Page 4

32 to 58. (Canceled)